| ID |
date |
title |
| 627 |
1/8/2004 |
Neuroscience 2003 Reports Available at MDVU
|
| 628 |
1/12/2004 |
Dyskinesia Benefit of Amantadine is Short-Lived
|
| 629 |
1/23/2004 |
Pramipexole for REM Sleep Behavior Disorder
|
| 630 |
1/23/2004 |
Comorbidities in Parkinsonism
|
| 631 |
1/26/2004 |
Announcement: Innovative Educational Opportunity from WE MOVE
|
| 632 |
2/4/2004 |
Trehalose Sugar Reduces Aggregation in HD Mice
|
| 633 |
2/20/2004 |
Incidence and Consequences of Spasticity After Stroke
|
| 634 |
2/27/2004 |
Pathogenic Role of Excess Normal Alpha-Synuclein Confirmed in Second Family
|
| 635 |
3/15/2004 |
STN DBS Improves Sleep
|
| 636 |
3/23/2004 |
Announcement: WE MOVE Launches Online Educational Course on Pediatric Movement Disorders
|
| 637 |
3/26/2004 |
Long-term Follow-up of BTX-A for Cervical Dystonia
|
| 638 |
3/26/2004 |
Apomorphine Journal Supplement (Contents)
|
| 639 |
4/2/2004 |
Essential Tremor: Experimental Therapies
|
| 645 |
4/9/2004 |
Dystonia Cellular Pathophysiology, Alternative Medicine Use
|
| 646 |
4/9/2004 |
Dystonia Cellular Pathophysiology, Alternative Medicine Use
|
| 647 |
4/12/2004 |
RLS Prevalence, Co-Morbidities
|
| 648 |
4/13/2004 |
No Loss of Olfaction in Parkin PD
|
| 650 |
4/20/2004 |
Rasagiline May Slow PD Decline; Pergolide and Valvular Disease
|
| 652 |
4/21/2004 |
PARK6 Protein Identified; Case-Based Learning Modules Available
|
| 654 |
4/22/2004 |
FDA Approves Apomorphine Injectable; Trial of Fast-Dissolving Selegiline in PD
|
| 664 |
5/7/2004 |
Parkin Interacts with Ataxin2 and Synaptic Vesicle Proteins (AAN 2004)
|
| 666 |
5/11/2004 |
Long-term Results of GDNF Pilot Trial; Gene Therapy in Animal Model (AAN 2004)
|
| 668 |
5/12/2004 |
Dystonia: Altered Biochemistry of TorsinA, Genetics
|
| 670 |
5/13/2004 |
Essential Tremor Update (AAN 2004)
|
| 672 |
5/15/2004 |
Genetic Risk Factors in PD, part 1 (AAN 2004)
|
| 674 |
5/17/2004 |
RLS Prevalence, Diagnosis, and Severity (AAN 2004)
|
| 676 |
5/17/2004 |
Genetic Risk Factors for PD, part 2 (AAN 2004)
|
| 678 |
5/18/2004 |
Hallucinations in Advanced PD (AAN 2004)
|
| 680 |
5/18/2004 |
Announcement: New Educational Efforts from WE MOVE
|
| 682 |
5/19/2004 |
Dopamine Agonists for RLS (AAN 2004)
|
| 684 |
5/20/2004 |
Acetylcholinesterase Inhibitors for PD Dementia (AAN 2004)
|
| 686 |
5/24/2004 |
PD: Medication Errors, Most Troubling Symptoms (AAN 2004)
|
| 688 |
5/24/2004 |
RLS: Pilot Trials of New Therapies (AAN 2004)
|
| 690 |
5/25/2004 |
PD Dopamine Agonist Treatment (AAN 2004)
|
| 692 |
5/26/2004 |
PD: New Treatment Strategies in Animal Models (AAN 2004)
|
| 694 |
5/26/2004 |
Pediatric Movement Disorders (AAN 2004)
|
| 696 |
5/27/2004 |
BTX for Dystonias (AAN 2004)
|
| 698 |
5/28/2004 |
Psychogenic Movement Disorders (AAN 2004)
|
| 700 |
5/28/2004 |
Rasagiline Versus Entacapone in PD (AAN 2004)
|
| 702 |
5/31/2004 |
Tardive Dyskinesia Treatment and Risk Factors (AAN 2004)
|
| 704 |
6/28/2004 |
Environmental Risk Factors in PD
|
| 706 |
6/28/2004 |
ET Gene, FXTAS Prevalence
|
| 716 |
6/30/2004 |
Six-Month Double-blind GDNF Results Show No Benefit
|
| 718 |
7/5/2004 |
Botulinum Toxin News (MovDis 2004)
|
| 720 |
7/9/2004 |
Dystonia Research from Movement Disorders Congress 2004
|
| 722 |
7/19/2004 |
PD Treatment Update from Movement Disorders Congress 2004
|
| 728 |
7/22/2004 |
Miscellaneous Issues in Parkinson’s Disease from Movement Disorders Congress 2004
|
| 730 |
8/5/2004 |
Neuropsychiatric Aspects and Suicide Risk of DBS (MovDis Congress 2004)
|
| 731 |
8/5/2004 |
Neuropsychiatric Aspects and Suicide Risk of DBS (MovDis Congress 2004)
|
| 732 |
8/21/2004 |
Apathy and Testosterone; Sexuality After DBS in PD
|
| 734 |
8/21/2004 |
Systemic Proteasome Inhibitors Replicate Key Features of PD
|
| 736 |
8/21/2004 |
More Valvular Heart Disease from Ergot-Derived Dopamine Agonists
|
| 756 |
9/21/2004 |
New Case Study Added to Online Course: The Diagnosis and Management of Pediatric Movement Disorders
|
| 749 |
9/21/2004 |
TorsinA Functional Studies; Gene for Rapid-Onset Dystonia Parkinsonism
|
| 748 |
9/21/2004 |
BDNF, Mitochondrial Pore, RNAi in Polyglutamine diseases
|
| 755 |
9/21/2004 |
DBS for PD and Dystonia: Long-Term Results
|
| 760 |
9/29/2004 |
PD—Pain, Physical Therapy, Safinamide
|
| 762 |
10/8/2004 |
GDNF Withdrawn by Manufacturer; A vs B in CD (ANA 2004)
|
| 764 |
10/18/2004 |
Spasticity Treatment, AIMs Following Stroke; DBS Programmers' Forum
|
| 769 |
10/26/2004 |
PD Genetics Update
|
